2024欧洲肿瘤学会（ESMO 2024）年会即将来袭，此次会议将于欧洲中部夏令时间（CET）9月13日-17日在西班牙巴塞罗那举行。
近日，ESMO官方已公布所有口头摘要题目及作者信息。【肿瘤资讯】特别整理本次公布的肺癌相关专场Late-breaking abstracts（LBA）的重磅研究标题，以飨读者。
Proffered paper session: NSCLC metastatic
专场时间：2024年9月14日，08:30-10:00
专场地点：Barcelona Auditorium - Hall 2
摘要号：LBA52
Interim Analysis of GALAXIES Lung-201: Phase 2, Randomized, Open-label Platform Study of Belrestotug Plus Dostarlimab in Patients (pts) With Previously Untreated Locally Advanced/Metastatic (LA/M) PD-L1 High (TPS >/=50%) Non-Small Cell Lung Cancer (NSCLC)
GALAXIES Lung-201的中期分析：Belrestotug联合Dostarlimab治疗既往未经治疗的局部晚期/转移性（LA/M）PD-L1高水平（TPS >/=50%）非小细胞肺癌（NSCLC）患者的II期、随机化、开放标签平台研究
讲者：David R Spigel (Nashville, United States of America, TN)
摘要号：LBA53
Nivolumab (NIVO) plus relatlimab with platinum-doublet chemotherapy (PDCT) vs NIVO + PDCT as first-line (1L) treatment (tx) for stage IV or recurrent NSCLC: results from the randomized phase 2 RELATIVITY-104 study
纳武利尤单抗（NIVO)+relatlimab联合铂类双联化疗（PDCT）与NIVO+PDCT作为IV期或复发性NSCLC的一线（1 L）治疗（tx）：来自随机化II期RELATIVITY-104研究的结果
讲者：Nicolas Girard (Paris, France)
摘要号：LBA54
Amivantamab Plus Chemotherapy vs Chemotherapy in EGFR-mutated, Advanced Non-small Cell Lung Cancer After Disease Progression on Osimertinib: 2nd Interim Overall Survival From MARIPOSA-2
埃万妥单抗加化疗与化疗在EGFR突变的晚期非小细胞肺癌患者中的比较：接受奥希替尼治疗后疾病进展：MARIPOSA-2的第2个中期总生存期
讲者：Sanjay Popat (London, United Kingdom)
摘要号：LBA55
Mechanisms of Acquired Resistance to First-line Amivantamab Plus Lazertinib Versus Osimertinib in Patients With EGFR-mutant Advanced Non-Small Cell Lung Cancer: An Early Analysis from the Phase 3 MARIPOSA Study
EGFR突变型晚期非小细胞肺癌患者对一线埃万妥单抗 + Lazertinib与奥希替尼的获得性耐药机制：来自III期MARIPOSA研究的早期分析
讲者：Benjamin Besse (Villejuif, Cedex, France, CEDEX)
Proffered paper session: Non-metastatic NSCLC
专场时间：2024年9月13日，14:00-15:30
专场地点：Bilbao Auditorium - Hall 2
摘要号：LBA48
CCTG BR.31: A global, double-blind placebo-controlled, randomized phase III study of adjuvant durvalumab in completely resected non-small-cell lung cancer (NSCLC)
CCTG BR.31: 一项全球性的、双盲安慰剂对照的、随机的Ⅲ期研究，针对完全切除的非小细胞肺癌（NSCLC）进行了度伐利尤单抗辅助治疗
讲者：Glenwood Goss (Ottawa, Canada, Ontario)
摘要号：LBA81
Durvalumab (D) as consolidation therapy in limited-stage SCLC (LS-SCLC): outcomes by prior concurrent chemoradiotherapy (cCRT) regimen and prophylactic cranial irradiation (PCI) use in the ADRIATIC trial
度伐利尤单抗（D）作为局限期小细胞肺癌（LS-SCLC）巩固治疗：ADRIATIC试验中既往同步放化疗放疗（cCRT）方案和预防性颅内放疗（PCI）使用情况的结果
讲者：Suresh Senan (Amsterdam, Netherlands)
摘要号：LBA83
PECATI: A phase 2 trial to evaluate the efficacy and safety of lenvatinib in combination with pembrolizuma pretreated advanced B3-thymoma and thymic carcinoma
PECATI: 一项评价仑伐替尼联合帕博利珠单抗治疗晚期B3-胸腺瘤和胸腺癌的疗效和安全性的II期试验
讲者：Jordi Remon Masip (Villejuif, Cedex, France)
Mini oral session 1: Non-metastatic NSCLC
专场时间：2024年9月15日，10:15-11:30
专场地点：Barcelona Auditorium - Hall 2
摘要号：LBA49
Associations of ctDNA clearance (CL) during neoadjuvant Tx with pathological response and event-free survival (EFS) in pts with resectable NSCLC (R-NSCLC): expanded analyses from AEGEAN
可切除NSCLC（R-NSCLC）患者新辅助治疗期间ctDNA清除率（CL）与病理学缓解和无事件生存期（EFS）的相关性：来自AEGEAN的扩展分析
讲者：Martin Reck (Grosshansdorf, Germany)
摘要号：LBA50
Perioperative nivolumab (NIVO) v placebo (PBO) in patients (pts) with resectable NSCLC: clinical update from the phase 3 CheckMate 77T study
可切除NSCLC患者（患者）围手术期纳武利尤单抗（NIVO）与安慰剂（PBO）的比较：来自3期CheckMate 77T研究的临床更新
讲者：Mariano Provencio Pulla (Majadahonda, Spain, Madrid)
摘要号：LBA51
Circulating tumor DNA (ctDNA) dynamics and treatment responses in chemotherapy-ineligible patients (pts) with unresectable Stage III NSCLC from the phase 2 DUART trial
2期DUART试验中不适合化疗的不可切除III期NSCLC患者的循环肿瘤DNA（ctDNA）动力学和治疗应答
讲者：Andrea Riccardo Filippi (Milan, Italy)
Mini oral session: NSCLC metastatic
专场时间：2024年9月14日，10:15-11:45
专场地点：Santander Auditorium - Hall 5
摘要号：LBA56
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
在BRAF V600E突变型转移性NSCLC（mNSCLC）患者中开展的II期PHAROS研究中更新的Encorafenib + Binimetinib的疗效和安全性
讲者：Gregory J. Riely (New York, United States of America, NY)
摘要号：LBA57
Adagrasib (ADA) vs docetaxel (DOCE) in patients (pts) with KRASG12C-mutated advanced NSCLC and baseline brain metastases (BM): results from KRYSTAL-12
Adagrasib（ADA）与多西他赛（DOCE）在KRASG12C突变晚期NSCLC伴基底脑转移（BM）患者中的比较：KRYSTAL-12的结果
讲者：Fabrice Barlesi (Villejuif, France, CEDEX 20)
如有遗漏，欢迎留言补充！
排版编辑：肿瘤资讯-明小丽
苏公网安备32059002004080号
